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mated. Therefore prescriptions causing interaction coming from one ofﬁce should be 
prevented. But prescriptions from different ofﬁces cannot be avoided by the use of 
this isolated solution. Only a comprehensive e-health solution summoning up medica-
tion of a patient from different sources has the potential to improve patient safety. 
There are pharmacologic interactions with different clinical relevance.
PCV10
A META-ANALYSIS OF CARDIOVASCULAR RISK FACTORS: WHICH IS 
THE DIFFERENCE BETWEEN MEN AND WOMEN?
Villasis-Keever MA1, Rendón-Masías ME1, Pineda-Cruz R1, Escamilla-Nuñez A1, 
Mould-Quevedo JF2
1Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico, 2Pﬁzer S.A. de C.V., 
México City, Mexico
OBJECTIVES: The aim of this study was to conduct a meta-analysis to identify the 
potential differences of cardiovascular risk factors between men and women in 
primary prevention. METHODS: A systematic review was performed identifying 
prospective cohorts studies in which cardiovascular risk factors were analyzed 
(tobacco use, hypertension, diabetes, obesity and dyslipdemia) associated to the devel-
opment of acute myocardial infarction, angina pectoris or cardiovascular death, and 
in which results were segmented between men and women. The search was done in 
October 2009 in Medline, EMBASE and the Cochrane Collaboration. Two indepen-
dent reviewers identiﬁed the abstracts, selected full articles and extracted the data. 
Relative risk(RR) with 95% conﬁdence intervals (95%CI) were calculated. Random 
effects models were employed in the meta-analyses using Meta-Analyst v.2.0 software. 
A meta-regression was also conducted. RESULTS: From 3,712 studies, 21 cohort 
studies were selected. The number of participants among the trials varied between 
5,000 and 600,000 per study with a follow-up from 5 to 40 years. The meta-analyses 
showed that premenopausal women in comparison to men had a higher risk of having 
cardiovascular event when they have diabetes mellitus (RR 2.79 vs. 2.03), obesity 
(1.62 vs. 1.41), hypercholesterolemia (1.91 vs. 1.49), increase in LDL levels (2.08 vs. 
1.72) or increase in HDL levels (2.22 vs. 1.61); however, men showed higher risk of 
cardiovascular events when they have hypertension (RR 1.771; 95%CI 1.714–1.830 
vs. RR 1.812; 95%CI 1.759–2.305). In addition, women use of contraceptives was 
not a signiﬁcant cardiovascular risk factor. CONCLUSIONS: The majority of cardio-
vascular risk factors seem to be higher in premenopausal women rather than men. 
Preventive programs should include female population in other to avoid a greater 
number of cardiovascular events in the future.
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OBJECTIVES: To evaluate 1) use of diabetes and cardiovascular medications; 2) the 
associations of medication compliance with disease burden. METHODS: California 
Medicaid administrative data (2002–2004) were used to identify patients ≥40 years 
of age with a diagnosis of type II diabetes concurrent with any combination of the 
following cardiovascular diseases (CVD): hypertension (HYPT), coronary artery 
disease (CAD), and heart failure (HF). We assessed patients use of any appropriate 
diabetes or cardiovascular medication. Proportion of days covered ≥0.8 was used to 
evaluate medication compliance. Disease burden was deﬁned as any emergency or 
inpatient visit. Logistic regressions were used to identify factors associated with disease 
burden in 2004. RESULTS: We identiﬁed 21,740 patients. Fifty-six percent of patients 
ﬁlled both diabetes and cardiovascular medications. When compared to patients with 
comorbid HYPT(51%), those with two CVD conditions HF & CAD(69%) or HYPT 
& CAD(64%) were more likely to ﬁll both diabetes and cardiovascular medications 
(P < 0.0001). Approximately 43% of patients did not ﬁll or were noncompliant with 
appropriate medications. Major signiﬁcant factors associated with disease burden 
included CVD type vs. HYPT: HF & CAD (OR:3.19), HYPT & CAD (OR:1.55), HF 
(OR:2.12), and CAD (OR:2.31); comorbidities (OR:1.94); medications used vs. no 
appropriate medication ﬁlled: ﬁlled both diabetes and cardiovascular medications 
(OR:1.75), ﬁlled only diabetes medication (OR:1.54); noncompliance with medica-
tions vs. compliance with both medications: not ﬁlled or noncompliant (OR:1.75), or 
compliance with only diabetes (OR:1.35) or only cardiovascular medication 
(OR:1.20); two or more cardiovascular medication ﬁlls (OR:1.20). CONCLUSIONS: 
Prevalence of use for both appropriate diabetes and cardiovascular medications was 
low in diabetic patients with comorbid CVD. We identiﬁed multiple risk factors of 
disease burden, primarily those related to condition severity (based on proxy measures 
of comorbidity with two CVD or ﬁlling both diabetes and CVD medications), as well 
as not using or not complying with medications.
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OBJECTIVES: The objective of this study was to explore trends in high sensitivity 
C-reactive protein (hs-CRP) screening prior to statin use, as compared to current lipid 
screening practices. METHODS: The PharMetrics Integrated Outcomes Database was 
used to obtain medical claims records for continuously enrolled adult (≥18 years) 
ﬁrst-time statin users. Patients were followed for one year. Both hs-CRP and lipid tests 
were identiﬁed by CPT-4 procedure codes. Descriptive statistics were used to charac-
terize the population and estimate unadjusted associations between patient character-
istics and hs-CRP testing. Multivariable logistic regression was used to estimate the 
odds of testing, controlling for age, gender, diabetes, statin intensity, prescribing physi-
cian specialty, geographic region and health plan type. RESULTS: Between July 1, 
1997 and March 31, 2007, 33,666 new statin users received lipid tests within 90 days 
prior to the index statin prescription. One thousand (3%) also received hs-CRP tests 
during this time. Over 80% of these individuals received the tests in 2004 or later. 
Those receiving hs-CRP tests were less likely to have a Medicare, Medicaid or other 
type of plan, as compared to private insurance (P < .05) and were less likely to reside 
in the South, Midwest or West, as compared to the Northeast (P < 0.01). Individuals 
who received hs-CRP tests had higher adjusted odds of receiving a high potency statin 
(OR = 1.37, P < .01) and lower odds of having diabetes (OR = 0.56, P < 0.01). Those 
receiving hs-CRP tests were more likely to have a cardiologist as their statin-prescrib-
ing physician, rather than a family or general practitioner (OR = 1.31, P = 0.02). 
CONCLUSIONS: Rates of hs-CRP testing are very low, but higher among those seeing 
a cardiologist or having private insurance. Those who received a high potency statin 
had higher rates of testing, suggesting that those with higher cardiovascular risk may 
be more likely to receive an hs-CRP test.
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OBJECTIVES: Antithrombotic therapy is effective in preventing thromboembolic 
diseases, and it has been recommended by several international guidelines to prevent 
deep vein thrombosis (DVT) after major orthopedic surgeries under carefully monitor-
ing bleeding risks. To establish Taiwanese local guidance, this case study aims to 
evaluate the current utilization and effectiveness of antithrombotic agents for prevent-
ing DVT after total hip replacement (THR). METHODS: This one-year retrospective 
cohort study was conducted at a medical center in Southern Taiwan from May 2008 
to April 2009. Adult patients (above 18 years) who had undergone primary THR were 
identiﬁed by inpatient electronic database. Their medical records were reviewed from 
surgery date to three months post-operation for collecting demographic details and 
DVT-related clinical symptoms as the surrogate of effectiveness. Descriptive statistic 
and time-to-event analysis were then conducted. RESULTS: Medical records of 82 
patients (57.32% women) were reviewed. The average age is 59.15 ± 13.43 years and 
the mean body mass index is 25.20 ± 4.86 kg/m2. Only 31 out of the 82 patients 
(37.80%) had ever received prophylactic antithrombotic agents after surgery and all 
of them used aspirin, but only 22 patients used aspirin for more than 10 days. Twelve 
patients presented DVT symptoms after surgery but only one is from prophylactic 
group. Independent relative risk of DVT for patients without prophylaxis is 8.25 folds 
of patients with prophylaxis (95% conﬁdence interval: 1.48, 154.91). DVT symptoms 
mainly (91.67%) occurred within 15 days after THR and the median duration to 
symptoms presentation is 12 days. CONCLUSIONS: Antithrombotic therapy is not 
commonly used to prevent DVT after THR in this medical center. Aspirin alone seems 
effectively reduces the risk of DVT-related symptoms. It is necessary to further inves-
tigate the effectiveness of prophylactic antithrombotic agents after THR from Taiwan-
ese population-based database and explore the potential genetic factors inﬂuencing 
the effectiveness of antithrombotic therapy.
PCV14
COMPARATIVE EFFECTIVENESS ANALYSIS IDENTIFIES A SUPERIOR 
POINT OF CARE DEVICE FOR ASSESSING THE INTERNATIONAL 
NORMALIZED RATIO
Shermock KM1, Streiff MB2, Kraus P1, Pinto BL1, Lavallee DM3
1The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 2The Johns Hopkins University 
School of Medicine, Baltimore, MD, USA, 3Lovelace Respiratory Research Institute, Sykesville, 
MD, USA
OBJECTIVES: Comparative effectiveness research identiﬁes superior clinical devices 
or treatments through head-to-head comparisons. This study describes the use of an 
innovative framework to assess the quality and safety of two INR Point of Care 
devices. METHODS: Patients enrolled in the hematology Anticoagulation Manage-
ment Service provided three INR measures: one venous sample analyzed by our lab 
(considered the standard measure), one ﬁngerstick analyzed by the Hemochron Sig-
nature Elite POC device and another ﬁngerstick by the Coaguchek XS Plus. Agreement 
between INR values from each device and the lab was assessed. Agreement was 
achieved when the INR measures were predicted by a novel, validated method to lead 
to the same clinical decision. Differences in agreement between the POC devices and 
the lab were assessed using McNemar’s test of paired proportions. RESULTS: Ninety-
nine subjects were enrolled into the study. There was signiﬁcantly less difference 
between INR values from the Coaguchek XS device and the lab compared to the 
Hemochron device (average absolute difference = 0.24 vs 0.41 p < 0.05). The Hemo-
chron device tended to report both high and low INR values were within the target 
range when the laboratory said otherwise. Consequently, the Hemochron device was 
signiﬁcantly more likely to lead to a different clinical decision than the core laboratory 
compared to the Coaguchek XS (30% vs. 18%, respectively; RR: 1.7, 95% CI: 1.1–
2.4, P = 0.007). CONCLUSIONS: Comparative effectiveness analysis can provide 
essential information to make informed decisions when selecting medical devices to 
